The global supply chain is getting a massive biological upgrade. Anzen Industries just secured $2.2 million in pre-seed funding to ditch traditional fermentation for a faster, cell-free future. This UK-born deeptech startup is now packing its bags for the US to scale its revolutionary enzyme reactor technology.
High Profile Backers Fuel the Expansion
This substantial financial injection marks a pivotal moment for the biotech sector. LocalGlobe and Creator Fund led the pre-seed round.
They were not alone in recognizing the potential here. Strategic angel investors from the UK, EU, and US also joined the round. Notable participants include Konstantin von Unger and early-stage investor Cory Levy.
The funding serves a dual purpose for founders Amy Locks and Pedro Lovatt Garcia. It validates their scientific breakthrough and provides the capital needed for a major geographic shift. Anzen plans to relocate its operations to the United States.
Amy Locks, CEO and co-founder, explained the strategic reasoning behind this move. She noted that while Europe provided the scientific foundation, the US offers the ideal environment for rapid commercial scaling.
modular enzyme reactor technology for chemical production
Escaping the Limits of Fermentation
To understand why this funding matters, we must look at how we currently make chemicals. Traditional biomanufacturing usually relies on fermentation. This involves growing massive amounts of living cells in giant vats to produce a tiny amount of a desired chemical.
It is an expensive and inefficient process.
Anzen Industries takes a first-principles approach known as cell-free biomanufacturing.
Instead of managing the complex needs of living cells, they extract the machinery. They use specific enzymes to perform chemical reactions directly. This removes the biological “noise” and energy waste associated with keeping cells alive.
Co-founder and CTO Pedro Lovatt Garcia highlighted the efficiency of this method. He stated that keeping enzymes robust outside the cell allows for manufacturing at a fraction of the cost and energy.
“We started Anzen Industries because we believe that, from first principles, the future of manufacturing will be cell-free.” — Pedro Lovatt Garcia
This technology utilizes reusable, low-infrastructure enzyme reactors. These modular units can produce complex molecules more efficiently than plant extraction or organic synthesis.
Why This Matters for Global Industries
The chemical industry has long struggled with supply chain fragility. We saw this clearly during recent global disruptions. Reliance on specific agricultural harvests or massive centralized factories creates bottlenecks.
Anzen promises to decentralize and democratize chemical production.
Their AI-driven design and proprietary enzyme immobilization techniques allow for smaller, flexible production sites. This is a game-changer for industries ranging from pharmaceuticals to food and beverage.
Here is how Anzen stacks up against traditional methods:
- Scalability: Moves from massive vats to modular reactors.
- Cost: Reduces capital expenditure by eliminating complex life-support systems for cells.
- Speed: Accelerates the time to market for new chemical products.
- Sustainability: Lowers energy consumption and physical footprint.
Julia Hawkins, General Partner at LocalGlobe, praised this vision. She noted that Anzen is rethinking production to improve resilience and control across global supply chains.
The Road Ahead for Anzen
The immediate future for Anzen involves establishing a physical footprint in America. The $2.2 million will fund their first dedicated manufacturing facility.
This facility will serve as the proving ground for their technology at an industrial scale.
Beyond physical infrastructure, the company is aggressively expanding its network. They plan to forge industrial collaborations to test their reactors on real-world chemical problems.
The goal is to prove that biology can outpace traditional chemistry without the baggage of living cells.
Competition in the deeptech space is fierce. However, Anzen’s focus on reusable enzymes sets them apart from competitors who still rely on single-use processes.
This funding round is just the beginning. As they settle into the US market, the industry will be watching to see if their modular reactors can deliver on their high-yield promises.
Anzen Industries is betting that the future of chemistry is biological but not alive. With $2.2 million in the bank and a move to the US confirmed, they are well-positioned to prove it. This shift could redefine how we source everything from medicines to flavorings in the coming decade.
